325 related articles for article (PubMed ID: 33581791)
1. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
3. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
[TBL] [Abstract][Full Text] [Related]
4. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
[TBL] [Abstract][Full Text] [Related]
5. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C
J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347
[TBL] [Abstract][Full Text] [Related]
7. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
Singh N; Goyal V
J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in AChR subtype of myasthenia gravis: systematic review.
Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874
[TBL] [Abstract][Full Text] [Related]
10. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis.
Robeson KR; Kumar A; Keung B; DiCapua DB; Grodinsky E; Patwa HS; Stathopoulos PA; Goldstein JM; O'Connor KC; Nowak RJ
JAMA Neurol; 2017 Jan; 74(1):60-66. PubMed ID: 27893014
[TBL] [Abstract][Full Text] [Related]
11. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
Jing S; Song Y; Song J; Pang S; Quan C; Zhou L; Huang Y; Lu J; Xi J; Zhao C
J Neuroimmunol; 2017 Oct; 311():14-21. PubMed ID: 28789841
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.
Ren J; Wang J; Liu R; Jin Y; Guo J; Yao Y; Luo J; Hao H; Gao F
Eur Neurol; 2023; 86(6):387-394. PubMed ID: 37778340
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
16. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis.
Zingariello CD; Elder ME; Kang PB
Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658
[TBL] [Abstract][Full Text] [Related]
17. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
[TBL] [Abstract][Full Text] [Related]
18. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
[TBL] [Abstract][Full Text] [Related]
19. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
Stieglbauer K; Pichler R; Topakian R
J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
[TBL] [Abstract][Full Text] [Related]
20. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]